Haemonetics Corporation
HAE
$78.71
$3.835.12%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.76% | -2.75% | -5.27% | -4.40% | -3.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.76% | -2.75% | -5.27% | -4.40% | -3.70% |
| Cost of Revenue | 12.67% | -10.09% | -14.00% | -17.43% | -14.84% |
| Gross Profit | -0.45% | 2.93% | 1.78% | 7.01% | 5.41% |
| SG&A Expenses | 8.35% | 0.17% | -4.70% | -1.41% | 0.44% |
| Depreciation & Amortization | -7.13% | -10.61% | -8.82% | -8.65% | 8.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.44% | -6.30% | -9.53% | -10.08% | -6.40% |
| Operating Income | -13.44% | 13.42% | 15.12% | 27.38% | 12.40% |
| Income Before Tax | -140.15% | 20.15% | 14.72% | -3.31% | 202.11% |
| Income Tax Expenses | -164.69% | 22.64% | 15.89% | 33.55% | 318.64% |
| Earnings from Continuing Operations | -134.75% | 19.33% | 14.34% | -11.32% | 184.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.75% | 19.33% | 14.34% | -11.32% | 184.68% |
| EBIT | -13.44% | 13.42% | 15.12% | 27.38% | 12.40% |
| EBITDA | -10.06% | 7.39% | 9.08% | 16.95% | 12.56% |
| EPS Basic | -136.98% | 28.23% | 22.30% | -6.11% | 193.92% |
| Normalized Basic EPS | -26.78% | 27.73% | 24.83% | 2.77% | 32.28% |
| EPS Diluted | -137.05% | 28.38% | 22.73% | -5.41% | 194.65% |
| Normalized Diluted EPS | -26.36% | 28.09% | 25.48% | 3.52% | 33.14% |
| Average Basic Shares Outstanding | -6.04% | -6.95% | -6.50% | -5.56% | -3.14% |
| Average Diluted Shares Outstanding | -6.57% | -7.21% | -6.98% | -6.23% | -3.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |